<?xml version="1.0" encoding="UTF-8"?>
<p>Pharmacotherapy for leishmaniasis treatment and Chagas disease is a little bit scarce (
 <xref rid="B4" ref-type="bibr">4</xref>). This is due to commercial disinterest reflected by the fact that the parasitic diseases mainly affect developing countries, where the population has low purchasing power, leading to a low yield for factories, because the drugs would have to be affordable (
 <xref rid="B5" ref-type="bibr">5</xref>).
</p>
